Skip to content

TAPENTADOL NASAL SPRAY FOR PAIN CONTROL POST EXTRACTION

TAPENTADOL NASAL SPRAY: A FUTURISTIC MODALITY OF PAIN CONTROL IN POST EXTRACTION CASES

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/043654
Enrollment
15
Registered
2022-07-01
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K041- Necrosis of pulp

Interventions

Intervention1: Tapentadol: POST ATRAUMATIC EXTRACTION, PATIENT WILL BE ADMINISTERED TAPENTADOL NASAL SPRAY. route - nasal dose-45 mg QID frequency- every 6th hourly total duration- 3 days Control Inte

Sponsors

MD KHIZAR HUSSAIN MAZHARI
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: PATIENT REQUIRING BILATERAL EXTRACTION CASES WILL BE CHOSEN UP FOR THE STUDY. PATIENTS BETWEEN AGE GROUP OF 15-50 WILL BE TAKEN UP FOR THE STUDY. PATIENTS WHO ARE MEDICALLY FIT WOULD BE TAKEN UP FOR THE STUDY

Exclusion criteria

Exclusion criteria: PATIENT ALLERGIC TO DRUGS WIIL BE EXCLUDED. PATIENTS, WHO REQUIRE TRAUMATIC EXTRACTIONS, AND PATIENT WITH ANY UNDERLYING PATHOLOGY WILL BE SPARED. PATIENTS WHO HAVE HISTORY OF NASAL PATHOLOGY VIZ RHINITIS, POLYPS, DEVIATED NASAL SEPTUM WOULD BE SPARED

Design outcomes

Primary

MeasureTime frame
pain will be assessed based on visual analogue scaleTimepoint: 3rd day

Secondary

MeasureTime frame
pain assessment and comparision with Non steroidal anti inflammatory drugTimepoint: 7th day

Countries

India

Contacts

Public ContactMD KHIZAR HUSSAIN MAZHARI

YENEPOYA DENTAL COLLEGE

jagadishmds@rediffmail.com9845150871

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026